Pittsburgh Magazine Honors Amanda McQuillan

Pittsburgh Magazine recognizes Amanda McQuillan as a 2026 40 Under 40 honoree for her work in biotech innovation.

Updated on Oct. 30, 2026 in Biotech

Isometric editorial illustration of laboratory pipettes and a DNA helix model on a metallic surface, representing biotech innovation. — Pittsburgh Magazine named Amanda McQuillan, an executive at CVP, a 2026 40 Under 40 honoree for her leadership in veteran pharmacogenomics programs. AI Illustration. Upload story photo >

Pittsburgh Magazine has named Amanda McQuillan, Executive Director of Business Transformation at CVP, a 2026 40 Under 40 honoree. Her leadership includes expanding a pharmacogenomics program across nine VA health systems to improve veteran care.

Why it matters

The program McQuillan helped advance uses genetic testing to tailor medical treatments, directly impacting how thousands of veterans receive care for complex health conditions.

The pharmacogenomics program analyzes patient DNA to evaluate medication efficacy and dosage for 22 specific genes affecting over 100 medications. More than 1,200 healthcare providers currently utilize the testing platform.

The players

Amanda McQuillan

She is the Executive Director of Business Transformation at CVP and a veteran of the VA Pittsburgh healthcare system.

UPMC Children's Hospital

This is a leading pediatric medical center in Pennsylvania where McQuillan raises funds and advocates for patient care.

CVP

This is a consulting and technology firm where McQuillan manages business transformation efforts.

The details

McQuillan spent 12 years at VA Pittsburgh, where she helped scale the testing platform to support patient safety and medication management. Beyond her professional work in biotech, she is a dedicated advocate for UPMC Children's Hospital.

Amanda McQuillan was named a 2026 40 Under 40 honoree.

The Tech Race

The program represents a major effort within the VA's clinical pharmacogenomics initiative, establishing a model for large-scale integration of personalized medicine. It marks a shift from standardized prescribing toward data-driven, genetic-based treatment protocols.

For patients within the VA system, this program streamlines the selection of effective medications while minimizing dangerous side effects. It demonstrates how genomic data is increasingly used to improve clinical outcomes and personalized patient care.

The takeaway

Advancements in pharmacogenomics demonstrate the growing importance of utilizing patient DNA to tailor medical treatments. Integrating genetic testing into routine care helps healthcare providers move toward more precise, individualized therapy.